{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:34:40Z","timestamp":1792503280656,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T-cell (CART) therapy can significantly improve outcomes for patients with certain hematologic malignancies. The most notable drawbacks of CART are cytokine release syndrome and CART-related encephalopathy syndrome. Gastrointestinal adverse events (GI-AEs) have not yet been reported in association with CART. Herein, we describe the incidence and clinical features of GI-AEs observed after CART.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We report a case series of patients with hematologic malignancies who received CART, in a clinical trial or as the standard of care, and subsequently suffered from GI-AEs between 2012 and 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In our cohort, 37 of 132 (28%) patients experienced GI-AEs. All 37 experienced diarrhea with a median onset of 7 days (interquartile range, 4 to 25\u2009d) after CART infusion. The median age of these patients was 58 years. Most had diffuse large B-cell lymphoma (51%). Seventeen patients experienced cytokine release syndrome, and 9 experienced CART-related encephalopathy syndrome. The interleukin-6 antagonist was required in 15 patients. Overall, 49% of patients had grade 1 diarrhea, 32% had grade 2, and 15% had grade 3. Other gastrointestinal symptoms in these patients were abdominal pain (41%), nausea and vomiting (49%), fever (8%), bloody stools (3%), and abdominal distension (5%). The median duration of symptoms was 6 days (interquartile range, 3 to 9\u2009d). In 32 patients who underwent imaging, 8 (25%) had findings suggestive of gastrointestinal tract inflammation. Nine (24%) patients experienced GI-AE recurrence after initial improvement. The symptoms were attributed to an alternative cause in 17 (13%) cases and to CART in 20 (15%) cases. One patient developed CART-related refractory colitis that eventually responded to antibiotics for pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CART-related GI-AEs occur in 15% of patients treated with CART. These symptoms are typically mild and self-limiting, requiring only symptomatic treatment. Nevertheless, CART may, in rare cases, lead to refractory colitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/coc.0000000000000596","type":"journal-article","created":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T01:04:16Z","timestamp":1567386256000},"page":"789-796","source":"Crossref","is-referenced-by-count":39,"title":["Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy"],"prefix":"10.1097","volume":"42","author":[{"given":"Hamzah","family":"Abu-Sbeih","sequence":"first","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenglong","family":"Tang","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"},{"name":"Minimally Invasive Surgery Center, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal S.","family":"Ali","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Luo","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Lymphoma and Myeloma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Lymphoma and Myeloma"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo C.","family":"Okhuysen","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Infection Control & Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Chin","family":"Foo","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Curry","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Richards","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip S.","family":"Ge","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"Gastroenterology, Hepatology, and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMc1800913","article-title":"CAR T-cell therapy in large B-cell lymphoma","volume":"378","author":"Neelapu","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41419-018-0918-x","article-title":"The biological basis and clinical symptoms of CAR-T therapy-associated toxicites","volume":"9","author":"Titov","year":"2018","journal-title":"Cell Death Dis"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-02505-2_7","article-title":"Immune checkpoint inhibitors-induced colitis","volume":"995","author":"Tian","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40425-018-0461-4","article-title":"Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-018-0411-1","article-title":"Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis","volume":"6","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ibd\/izy240","article-title":"Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity?","volume":"25","author":"Choi","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s40425-018-0412-0","article-title":"Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis","volume":"6","author":"Johnson","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MEG.0000000000001288","article-title":"Recurrent Clostridium difficile infection is associated with treatment failure and prolonged illness in cancer patients","volume":"31","author":"Abu-Sbeih","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2016-0127","article-title":"Donor origin CART cells: graft versus malignancy effect without GVHD, a systematic review","volume":"9","author":"Anwer","year":"2017","journal-title":"Immunotherapy"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","article-title":"Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/JIPO.JIPO_12_18","article-title":"The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients\u2019 outcomes","volume":"1","author":"Abu-Sbeih","year":"2018","journal-title":"J Immunother Precision Oncol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T23:10:27Z","timestamp":1693696227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/COC.0000000000000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000596","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}